Compare Apollo Global Management Ord Shs (APO) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Novavax Inc — how do they compare? Apollo Global Management Ord Shs trades at $140.51 (market cap $82.84B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Apollo Global Management Ord Shs is far larger — about 63.2× Novavax Inc's market cap, and Apollo Global Management Ord Shs pays a 1.6% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| APO | NVAX | |
|---|---|---|
Market Cap | $82.84B | $1.31B |
Sector | Financials | Health |
52-Week High | $152.70 | $11.19 |
52-Week Low | $100.30 | $6.22 |
Enterprise Value | -$168.65B | $889.30M |
Dividend Yield | 1.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
